Three Brazilian isolates of bovine viral diarrhea virus (BVDV), antigenically distinct from the standard North American isolates, were selected to immunize BALB/c mice in order to obtain hybridoma cells secreting anti-BVDV monoclonal antibodies (mAbs). Two hybridoma clones secreting mAbs, reacting specifically with BVDV-infected cells (mAbs 3.1C4 and 6.F11), were selected after five fusions and screening of 1001 hypoxanthine-aminopterin-thymidine-resistant clones. These mAbs reacted in an indirect fluorescent antibody (IFA) assay with all 39 South and North American BVDV field isolates and reference strains available in our laboratory, yet failed to recognize other pestiviruses, namely the hog cholera virus. The mAbs reacted at dilutions up to 1:25,600 (ascitic fluid) and 1:100 (hybridoma culture supernatant) in IFA and immunoperoxidase (IPX) staining of BVDV-infected cells but only mAb 3.1C4 neutralized virus infectivity. Furthermore, both mAbs failed to recognize BVDV proteins by IPX in formalin-fixed paraffin-embedded tissues and following SDS-PAGE and immunoblot analysis of virus-infected cells, suggesting they are probably directed to conformational-type epitopes. The protein specificity of these mAbs was then determined by IFA staining of CV-1 cells transiently expressing each of the BVDV proteins: mAb 3.1C4 reacted with the structural protein E2/gp53 and mAb 6.F11 reacted with the structural protein E1/gp25. Both mAbs were shown to be of the IgG2a isotype. To our knowledge, these are the first mAbs produced against South American BVDV isolates and will certainly be useful for research and diagnostic purposes.

Seqüenciamento e análise filogenética de 17 amostras do vírus da diarréia viral bovina (BVDV) isoladas no Brasil identificaram quatro amostras (23,5%) do genótipo 1a (BVDV-1a), nove amostras (52,9%) do genótipo 1b (BVDV tipo 1b) e quatro amostras (23,5%) do genótipo 2 (BVDV tipo 2). As amostras brasileiras de BVDV tipo 2 apresentaram-se genotipicamente distintas dos BVDV tipo 2 até então identificados na América do Norte e Europa, sugerindo pertencerem a um novo subgenótipo. A caracterização antigênica dessas amostras por neutralização cruzada revelou reatividade sorológica muito reduzida com cepas vacinais do BVDV. O anti-soro produzido contra três cepas vacinais do BVDV apresentou atividade neutralizante muito reduzida contra várias amostras brasileiras de BVDV tipos 1 e 2. Diferenças de até 128 vezes nos títulos de anticorpos neutralizantes foram observadas entre cepas vacinais e amostras brasileiras do BVDV. Nos testes de soroneutralização (SN) contra o vírus dos tipos 1 e 2, de 1134 amostras testadas, 280 (24,7%) possuiam anticorpos neutralizantes anti-BVDV e dessas, 215 (76,8%) apresentaram atividade neutralizante contra ambos os vírus, 37 (13,2%) reagiram apenas contra o BVDV tipo 2 e 28 amostras (10%) foram positivas apenas contra o BVDV tipo 1. Esses resultados demonstram que testes de SN utilizando vírus de apenas um genótipo podem resultar em um número significativo de falsos-negativos e indica a necessidade da formulação de vacinas com amostras locais de BVDV e/ou contendo vírus dos dois genótipos.

Nucleotide sequencing and phylogenetic analysis of 17 Brazilian isolates of bovine viral diarrhea virus (BVDV) identified four isolates (23.5%) belonging to genotype 1a (BVDV-1a), nine isolates (52.9%) of the genotype 1b (BVDV-1b) and four isolates (23.5%) belonging to genotype 2 (BVDV-2). The Brazilian BVDV type 2 isolates were shown to be genotypically different from the BVDV type 2 identified so far in North America and Europe, suggesting they might belong to a new subgenotype. Antigenic characterization of these isolates by cross-neutralization revealed a very low serologic cross-reactivity with vaccine BVDV strains. The immune serum raised in lambs to three vaccine strains presented a very low and even negligible neutralizing activity against some Brazilian BVDV type 1 and 2 isolates. Up to 128-fold differences in serum neutralizing antibody titers were observed between the vaccine strains and some Brazilian BVDV isolates. The potential impact of the antigenic variability of BVDV on serologic diagnosis was investigated by testing field serum samples by serum-neutralization (SN) against viruses of both genotypes. Two hundred and eighty samples (24.7%) had neutralizing antibodies against BVDV. Out of these, 215 (76.8%) had neutralizing activity against viruses of both genotypes, 37 samples (13.2%) reacted only against BVDV type 2 and 28 (10%) were positive only to BVDV type 1. These results demonstrate that SN tests using only one virus may result in a significant number of false-negative results. The reduced neutralizing activity of the antisera to vaccine strains against some Brazilian isolates raises the question about the degree of protection conferred by these vaccines and indicates the need of producing vaccines based on local viruses and/or including viruses of both genotypes.